Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within two randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment 106/190 evaluable patients (56%) achiev...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pott, Christiane, Hoster, Eva, Delfau-Larue, Marie-Hélène, Beldjord, Kheira, Böttcher, Sebastian, Asnafi, Vahid, Plonquet, Anne, Siebert, Reiner, Callet-Bauchu, Evelyne, Andersen, Niels, Van Dongen, Jacques J. M., Klapper, Wolfram, Berger, Françoise, Ribrag, Vincent, Van Hoof, Achiel L., Trneny, Marek, Walewski, Jan, Dreger, Peter, Unterhalt, Michael, Hiddemann, Wolfgang, Kneba, Michael, Kluin-Nelemans, Hanneke C., Hermine, Olivier, Macintyre, Elizabeth, Dreyling, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2930903/
https://ncbi.nlm.nih.gov/pubmed/20032498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-06-230250
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados